Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of Cutaneous T-cell Lymphomas (CTCL), providing valuable options (4).
In the context of Mogamulizumab & Cutaneous T-Cell Lymphoma (CTLC), the US FDA approved mogamulizumab in August 2018 for adult patients with relapsed or refractory Cutaneous T-Cell Lymphoma (CTLC) (specifically the two major subtypes mycosis fungoides or [Sézary syndrome](brain://06xbQ_rh0kCzNHmuPLx0Ww/S%C3%A9z…